Good Samaritan Regional Medical Center (Oregon)

Frontier Dermatology Announces Co-Chief Medical Officer Appointments to Elevate Regional Patient Care

Retrieved on: 
Tuesday, October 31, 2023
FAAD, Psoriasis, DO, Dermatology, Good Samaritan Regional Medical Center (Oregon), Clinical research, Pacific Northwest, Y Touring Theatre Company, Health, Skin, Growth, The Company, CMOS, Atopic dermatitis, CMO, Patient, Associate, Management, Medical device, MD

PORTLAND, Ore. and SEATTLE, Oct. 31, 2023 /PRNewswire/ -- Frontier Dermatology (or the "Company"), the Pacific Northwest's top authority on medical and cosmetic skin care, is updating its organizational structure by introducing Co-Chief Medical Officer ("Co-CMO") roles.

Key Points: 
  • PORTLAND, Ore. and SEATTLE, Oct. 31, 2023 /PRNewswire/ -- Frontier Dermatology (or the "Company"), the Pacific Northwest's top authority on medical and cosmetic skin care, is updating its organizational structure by introducing Co-Chief Medical Officer ("Co-CMO") roles.
  • Having recently united nine legacy practice brands under the Frontier Dermatology banner , this new leadership structure will enhance the organization's ability to deliver localized, high-quality patient care while maintaining a unified, super-regional vision.
  • Dr. Lauren Boudreaux , known for her comprehensive approach to dermatology, previously served as Frontier Dermatology's Chair of the Medical Advisory Board's Cosmetics Committee, Regional Medical Director for the South Region (Oregon), and Associate Chief Medical Officer.
  • Bill Frerichs, President and Chief Operating Officer of Frontier Dermatology, remarked, "Dr. Schmidt's visionary leadership has been instrumental in positioning Frontier Dermatology at the forefront of patient care in the Pacific Northwest.

Ipsen appoints Sandra Silvestri as EVP, Chief Medical Officer and Head of Global Medical Affairs, Patient Safety and Patient Affairs

Retrieved on: 
Monday, April 24, 2023
IPN, Medicine, Endocrinology, Medical Affairs Bureau, Emergency medicine, ADR, Internal medicine, Genetics, Pharmacogenomics, EVP, Cardiovascular disease, ELT, Eli Lilly, Good Samaritan Regional Medical Center (Oregon), Patient, DSM-IV codes, Physician, Scientific communication, Patient safety, Medical device, Pharmaceutical industry, Ipsen, Euronext, Sanofi

Ipsen appoints Sandra Silvestri as EVP, Chief Medical Officer and Head of Global Medical Affairs, Patient Safety and Patient Affairs

Key Points: 
  • Ipsen appoints Sandra Silvestri as EVP, Chief Medical Officer and Head of Global Medical Affairs, Patient Safety and Patient Affairs
    PARIS, FRANCE, 24 April 2023 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical company, announced today the appointment of Sandra Silvestri, M.D., Ph.D., as EVP, Chief Medical Officer and Head of Global Medical Affairs, Patient Safety and Patient Affairs, effective 5 May 2023.
  • Sandra brings years of extensive medical experience in the global biopharmaceutical industry and joins Ipsen after spending eight years at Sanofi.
  • Since 2020, she has served as Senior Vice President and Chief Medical Officer of the General Medicines Global Business Unit, and Global Head of Medical Affairs Capabilities Centre of Excellence and Medical Hub, where she was responsible for worldwide medical affairs strategy and execution.
  • Steven Hildemann, M.D., Ph.D., who served as Ipsen’s Chief Medical Officer for three years and successfully led a deep transformation of Global Medical Affairs and Patient Safety, will leave Ipsen to pursue other opportunities after handing over to Sandra.

PHP/IOP Behavioral Health Reacts to Maryland Teen Suffering in Waiting Room for 76 Days; Provides Critical Solution to Ongoing Crisis

Retrieved on: 
Wednesday, November 2, 2022
American Academy, Partial hospitalization, Mental health, Pediatrics (journal), ER, The Washington Post, The New York Times, OCD, American Academy of Child and Adolescent Psychiatry, GLOBE, Psychiatry, Children's Hospital Association, RSV, Good Samaritan Regional Medical Center (Oregon), IOP, Anxiety, PHP, Trauma, Adolescence, Intensive outpatient program, Ontario Hospital Association, Patient, Pediatrics, Association, Solution, Depression, Hospital, Residential care, MD, Compass, Child

Partial Hospitalization (PHP) and Intensive Outpatient (IOP) programs, like Compass Health Center, are helping to provide solutions.

Key Points: 
  • Partial Hospitalization (PHP) and Intensive Outpatient (IOP) programs, like Compass Health Center, are helping to provide solutions.
  • Mental Health treatment spans a continuum of care, with outpatient support on one end and inpatient and residential care on the other.
  • Compass provides PHP and IOP programs for patients in crisis experiencing symptoms of depression, anxiety, suicidal thinking, trauma, or OCD.
  • Compass Health Center plans to expand its in-person and virtual treatment options outside of Illinois to Maryland in the spring of 2023.

Silver Bullet Therapeutics Launches OrthoFuzIon® Bone Screw System at DKOU German Congress of Orthopedics and Traumatology

Retrieved on: 
Monday, October 25, 2021
Surgeon, Therapy, ICS Learn (International Correspondence Schools), GLOBE, American Academy, Incidence, Infection, Culture, Osteomyelitis, Silver Bullet, Silver, Elective surgery, Solution, Deutsche Gesellschaft für Internationale Zusammenarbeit, Subclinical infection, SAN, CA, Risk, Trademark, Platinum, Disease, CEO, Environment, Sale, Patient, University of California, Irvine Medical Center, ORIF, MD, Technology, University, Injury, FDA, Congress, Journal, Good Samaritan Regional Medical Center (Oregon), Pharmaceutical industry, Dentistry

SAN JOSE, Calif., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Silver Bullet Therapeutics, Inc., a privately-held medical device company, announced today that it is formally launching its antimicrobial OrthoFuzIon Bone Screw System at the DKOU German Congress of Orthopedics and Traumatology on October 26-29 in Berlin.

Key Points: 
  • SAN JOSE, Calif., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Silver Bullet Therapeutics, Inc., a privately-held medical device company, announced today that it is formally launching its antimicrobial OrthoFuzIon Bone Screw System at the DKOU German Congress of Orthopedics and Traumatology on October 26-29 in Berlin.
  • The OrthoFuzIon Orthopedic Bone Screw System is a comprehensive antimicrobial bone screw product line for orthopedic procedures.
  • Paul Chirico, President and CEO of Silver Bullet Therapeutics stated, Silver Bullet is very excited to be launching our product line at the prestigious German Society of Orthopedics with Argomedical, our respected distribution partner.
  • The Silver Bullet Therapeutics antimicrobial OrthoFuzIon Bone Screw System is not only simple but a disruptive medical device that may change the practice of trauma orthopedics almost immediately.